Trial
NCT03541369
Safety, Tolerability, PK, PD, and Efficacy of AMG 427 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Amgen
Collaborators
—
Condition
Relapsed/Refractory Acute Myeloid Leukemia (AML)
Intervention
AMG 427
Why stopped
Premature discontinuation of study, a strategic decision.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-10-10